We want to connect, learn from and work with you.
Multi-stakeholder community to promote patient access to novel cellular therapies
WHO WE ARE
GoCART is a multi-stakeholder coalition of patient representatives, health care professionals, pharmaceutical companies, regulators, Health Technology Assessment (HTA) bodies and reimbursement agencies, and medical organisations, collaborating to maximise the potential of cellular therapies manufactured from cells and tissues of haematopoietic origin.
What is car t?
Chimeric Antigen Receptor T-cell therapy (CAR T) is a type of cell-based gene therapy where the patient becomes their own donor. In CAR T, the patient’s T cells are collected and genetically engineered to contain a receptor that recognises the patient’s cancer cells. These genetically engineered T cells are injected back into the patient and can now attack cancer cells which were previously hidden to the immune system.
Events
The European Hematology Association (EHA) and the EBMT are organising the 6th European CAR T-cell meeting in Valencia, Spain on 15-17 February, 2024. For more information about the meeting, see: …
6th European CAR T-cell meeting Read More »
Find out more »
The 50th EBMT Annual Meeting will take place in Glasgow, United Kingdom on April 14-17, 2024. The Annual Meeting of the EBMT is an event for all those involved in …
EBMT 50th Annual Meeting Read More »
Find out more »
EHA2024's Annual Congress will take place in Madrid, Spain from June 13-16. For more information, see the congress website.
Find out more »Our GOALS
- Improve health outcomes
- Engage stakeholders and establish a sustainable European coalition
- Collaborate and share data and knowledge
- Promote harmonisation
- Set-up a central registry
Our founders
